A heart-rate-reducing medication reduces the risk of heart failure and cardiac fibrosis

The findings of a Montreal Heart Institute (MHI) study published in the scientific journal Cardiology suggest that ivabradine, a heart rate reduction medication, is also effective in reducing the risk of diastolic heart failure (left ventricular insufficiency) and cardiac fibrosis.

The benefits of slower on mortality and morbidity associated with cardiovascular disease no longer need to be demonstrated. In this study, titled "Heart Rate Reduction by Ivabradine Reduces Diastolic Dysfunction and Cardiac ," researchers sought to determine the effectiveness of ivabradine in treating diastolic dysfunction of the , a condition affecting 40% of people with heart failure.

The study was conducted on rabbits given a standard diet, a cholesterol-enriched diet or a cholesterol-enriched diet with ivabradine. It revealed that as well as improving the myocardial performance index, ivabradine greatly improved left ventricular diastolic dysfunction in animals receiving a cholesterol-enriched diet. Ivabradine also reduced fibrosis of the heart chambers.

According to Dr. Jean-Claude Tardif, Director of the MHI Research Centre and professor of medicine at the Université de Montréal, the results are both interesting and encouraging. "The effectiveness of ivabradine in treating angina pectoris is now well known. However, few treatments are available to patients with diastolic . The beneficial effects of ivabradine demonstrated in laboratory suggest that this course of treatment should be further investigated." Clinical studies with subjects are expected to follow.

Provided by Montreal Heart Institute

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Nuclear stress test can detect more than blockages

Jul 14, 2008

A less invasive test commonly used to diagnose coronary disease also may be used to detect one of the leading causes of heart failure, say researchers at the Medical College of Georgia.

Recommended for you

How Alzheimer's peptides shut down cellular powerhouses

16 hours ago

The failing in the work of nerve cells: An international team of researchers led by Prof. Dr. Chris Meisinger from the Institute of Biochemistry and Molecular Biology of the University of Freiburg has discovered ...

User comments